Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014  America,s future engineers will connect ... at the  Medical Design and Manufacturing (MD&M) Minneapolis ... at the Minneapolis ... built robots from the "For Inspiration and Recognition ... and mentors will offer information to those curious ...
(Date:10/25/2014)... 2014  The National Association of Drug Diversion ... by Kentucky,s real-time, stop-sale ... National Precursor Log Exchange (NPLEx) system automatically blocks ... and helps flag meth offenders for law enforcement. ... NPLEx "watch lists" that notify them via email ...
(Date:10/25/2014)... Oct. 24, 2014 In conjunction with DURECT ... financial results press release, you are invited to listen ... over the internet on Monday, November 3, 2014 at ... A live audio webcast of the presentation will ... and clicking "Investor Relations."  If you are unable ...
Breaking Medicine Technology:Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Kentucky's NPLEx Technology Making Significant Progress 2DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
(Date:10/25/2014)... October 25, 2014 Market ... Diagnostics Industry, 2009-2019 is a professional and ... Molecular Diagnostics industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Molecular Diagnostics listing their product ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 Mesothelioma researchers ... continued to receive pemetrexed (Alimta), after his combination drug ... the full story , just posted on the Surviving ... Uji Tokushukai Medical Center in Japan suggests that “maintenance ... mesothelioma patients who cannot tolerate higher doses of ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... increased risks for certain cancers, one might think that high-risk ... a new study suggests that, at least with colon cancer, ... genes doubled their risk of colon cancer were no more ... "It didn,t make any difference, not at all," said study ...
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... - Scientists from the Hebrew University have identified the molecular ... findings of this research have just been published in the ... the entire genetic information required for building the proteins of ... to changes in the cell function. These changes can lead ...
... of the brain,s master circadian clock known as the ... of rhythmic neural activity begins to decline by middle age. ... may have implications for the large number of older people ... "Aging has a profound effect on circadian timing," ...
... , TUESDAY, July 19 (HealthDay News) -- Following up ... for a long time have more gray matter in their ... shrink less as they age and they have stronger connections ... may better relay electrical signals, researchers said. "Our results ...
... triggering another, but explanations for that phenomenon have proved ... first neurobiological evidence that memories formed in the same ... episodic memory. The research was conducted by professor ... School of Arts and Sciences and graduate student Jeremy ...
... By Serena Gordon HealthDay Reporter , MONDAY, July 18 ... ride in a car driven by grandparents because they believe the ... But, new research suggests that children are actually safer in auto ... parent. As a matter of fact, the odds of ...
... , MONDAY, July 18 (HealthDay News) -- Melanoma, the ... by patients themselves, but new research reveals that self-detection ... In the study, conducted by researchers at Memorial ... found that in addition to higher rates of physician-detected ...
Cached Medicine News:Health News:Hebrew U. scientists identify molecular basis for DNA breakage 2Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 2Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 3Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 4Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 5Health News:Does Meditation Boost Brain Health? 2Health News:Penn researchers find neural signature of 'mental time travel' 2Health News:Kids Fare Better in Crashes When Grandparents Driving: Study 2Health News:Kids Fare Better in Crashes When Grandparents Driving: Study 3Health News:Specialists More Likely to Spot Deadly Skin Cancer 2
... Leica M844 F40 with its new stand F19 ... allow on the one hand to homogenously move ... operate with a solid and stable microscope. The ... Chrome optics, stands on the same small footprint ...
... 2000 assays are designed ... IMMULITE 2000, a high-throughput, ... analyzer. IMMULITE 2000 offers ... and a rapidly expanding ...
... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...
Inquire...
Medicine Products: